Traders should monitor upcoming clinical data readouts, particularly overall survival from the pancreatic cancer study and Phase 3 HCC results, as well as the company's ability to maintain cash runway through 2026 despite increasing losses. The recent $4.3 million financing reduces near-term dilution risk but may have led to share count increases.
Price Chart
Executive Summary
Can-Fite BioPharma reported its 2025 financial results, showing a 40% decline in revenue to $0.41 million and a widening net loss of $9.83 million, driven by higher R&D and administrative expenses. The company highlighted positive clinical developments, including a pancreatic cancer Phase 2a safety success, a 9-year cancer-free survival in a liver cancer patient, and IP expansion, while bolstering its cash position to $8.54 million through financing activities.
Key Facts
- Revenue for 2025 was $405,000, down 40% from $674,000 in 2024
- Net loss increased to $9.83 million in 2025 from $7.88 million in 2024
- R&D expenses rose 16.26% to $6.69 million, primarily for Namodenoson and Piclidenoson trials
- Cash and short-term deposits totaled $8.54 million as of December 31, 2025, up from $7.88 million in 2024
- On March 4, 2026, the company raised approximately $4.3 million from warrant exercises
- Phase 2a pancreatic cancer trial met primary safety endpoint; over 30% of patients alive at latest data cut-off
- A liver cancer patient treated with Namodenoson achieved over 9 years of cancer-free survival
- Complete resolution of esophageal varices observed in a decompensated cirrhosis patient
- Expanded Namodenoson's potential into obesity and metabolic diseases with new patents
Financial Impact
Revenue decreased by $269,000 year-over-year; net loss increased by $1.95 million. Cash position improved to $8.54 million after $4.3 million in warrant proceeds in early 2026.
Risk Factors
- Continuing revenue decline and increasing net losses raise sustainability concerns
- Heavy reliance on clinical trial outcomes for value creation
- Small market cap ($4M) increases volatility and sensitivity to funding news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-034417 |
| Document: ea0282971-6k_canfite.htm | 0001213900-26-034417 |
| Document: 0001213900-26-034417-index-headers.html | 0001213900-26-034417 |
| Document: 0001213900-26-034417-index.html | 0001213900-26-034417 |
| Document: 0001213900-26-034417.txt | 0001213900-26-034417 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.72 | awaiting T+5 | — | $1.72 (+0.00%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Oct 13, 2026 14d ago | EFFECT | $1.95 $1.89 | ▲ +3.08% | ▲ +1.93% | $1.72 (+11.79%) |
Sep 14, 2026 6w ago | EFFECT | $2.30 $2.22 | ▲ +3.48% | ▲ +3.58% | $1.72 (+25.22%) |
Sep 9, 2026 6w ago | 6-K | $2.19 $2.24 | ▲ +2.28% | ▲ +3.38% | $1.72 (−21.46%) |
Sep 3, 2026 7w ago | 6-K | $2.35 $2.33 | ▼ −0.85% | ▲ +0.30% | $1.72 (−26.81%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Sep 2, 2026 7w ago | Press Release | $2.36 $2.16 | ▲ +8.47% | ▲ +7.52% | $1.72 (+27.12%) |
Sep 2, 2026 7w ago | 6-K | $2.36 $2.16 | ▼ −8.47% | ▼ −7.52% | $1.72 (−27.12%) |
Aug 17, 2026 10w ago | 6-K | $3.58 $3.35 | ▼ −6.42% | ▼ −5.23% | $1.72 (−51.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers